|
|
Post by seanismorris on Nov 7, 2019 9:11:57 GMT -5
People here have been really impressed by the scripts graphs, but when you just look at number of scripts and number of years to get to this point, it’s not impressive.
MannKind has always been able to barrow money, the problem is it’s at the expense of shareholders. MC has had plenty of time to “right the ship” but he doesn’t have any answers with regards to Afrezza.
MC still runs the same old MannKind that lacks urgency and answers. Retraining the sales force is B.S. that’s a continuous process. MannKind will always have some “new” data to present suggesting all they need to do is get the word out.
I was hoping GoodRX was going to help with the retention rates (availability) but they’re saying “cough” is still a problem... that has to be the most pathetic excuse I've ever heard. That was a training issue from day one...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 7, 2019 9:19:59 GMT -5
People here have been really impressed by the scripts graphs, but when you just look at number of scripts and number of years to get to this point, it’s not impressive. MannKind has always been able to barrow money, the problem is it’s at the expense of shareholders. MC has had plenty of time to “right the ship” but he doesn’t have any answers with regards to Afrezza. MC still runs the same old MannKind that lacks urgency and answers. Retraining the sales force is B.S. that’s a continuous process. MannKind will always have some “new” data to present suggesting all they need to do is get the word out. I was hoping GoodRX was going to help with the retention rates (availability) but they’re saying “cough” is still a problem... that has to be the most pathetic excuse I've ever heard. That was a training issue from day one... You have to realize Afrezza is a drug ahead of it's time. Afrezza really works when you have a CGM. Diabetics will realize the effects of their insulin in REAL TIME when they get a CGM. As we saw last night DXCM and I'm sure Abbott and SENS are doing well in marketing their CGMs. That will be the time for Afrezza to take off. Diabetics will start to see their BGs in real time 24/7 and will very concerned as to why thier SC insulin works very slowly. Once they find Afrezza that paradigm with shift. Regarding righting the ship.....Shareholders did not fully understand the shape MNKD was in. MNKD was in BAD SHAPE and Mike has righted the ship. It will take more time to build momentum. |
|
|
|
Post by ktim on Nov 7, 2019 9:51:45 GMT -5
People here have been really impressed by the scripts graphs, but when you just look at number of scripts and number of years to get to this point, it’s not impressive. MannKind has always been able to barrow money, the problem is it’s at the expense of shareholders. MC has had plenty of time to “right the ship” but he doesn’t have any answers with regards to Afrezza. MC still runs the same old MannKind that lacks urgency and answers. Retraining the sales force is B.S. that’s a continuous process. MannKind will always have some “new” data to present suggesting all they need to do is get the word out. I was hoping GoodRX was going to help with the retention rates (availability) but they’re saying “cough” is still a problem... that has to be the most pathetic excuse I've ever heard. That was a training issue from day one... I think your first sentence should have started with "A very small number of people..." |
|
|
|
Post by letitride on Nov 7, 2019 10:10:26 GMT -5
If this was a preliminary is there a date that a final must be filed by ?
|
|
|
|
Post by Chris-C on Nov 7, 2019 10:18:30 GMT -5
People here have been really impressed by the scripts graphs, but when you just look at number of scripts and number of years to get to this point, it’s not impressive. MannKind has always been able to barrow money, the problem is it’s at the expense of shareholders. MC has had plenty of time to “right the ship” but he doesn’t have any answers with regards to Afrezza. MC still runs the same old MannKind that lacks urgency and answers. Retraining the sales force is B.S. that’s a continuous process. MannKind will always have some “new” data to present suggesting all they need to do is get the word out. I was hoping GoodRX was going to help with the retention rates (availability) but they’re saying “cough” is still a problem... that has to be the most pathetic excuse I've ever heard. That was a training issue from day one... -------- I'm a (too) long shareholder from pre-approval days, so I've been a firsthand witness to the trials and tribulations of this company. The company story is a novel in itself. If it were turned into a motion picture it could be anything from an agatha christie mystery to pearl harbor to a ground hog day comedy. Choose one or all. I haven't posted much lately because I've been coping with the sad reality of the pathetic goings on in this leaderless and morally bankrupt country. I'm also six figures underwater, so I'm just checking in occasionally to see how much progress is being made. Honestly, it is difficult to tell. At first I had great hope and faith in Castagna, who hit the ground running. But at some point, it feels like he morphed into another of the long line of well-intentioned but myopic executives who have squandered the company's value and failed to carry Al Mann's competence and enthusiasm across the goal line. It gets harder each year because the story of MNKD as a loser takes on the reputation of some fabled shipwreck. (Few are aware that the Titanic left on its maiden voyage with an unconfined (and undisclosed) fire in a boilerroom that weakened the hull at the approximate point of its impact with the ice (go figure!). Everyone who has followed this stock for a few years understands the challenges of Afrezza to the point of tedium. My recommendation to management would be to take the time to REALLY prioritize them, and then work with a greater sense of urgency to move the needle in substantial ways on the key points of resistance. Sometimes it feels like they'e just given up on success with Afrezza and turned their attention to other things (the pipeline). In the area of international sales, why not partner with companies who have the ability to get the job done, whether it involves regulatory approvals or distribution and sales? To encourage focus, hang the portraits of the past line of incompetent CEOS on the board with their three major debacles described and how they could have been avoided. Include a mugshot of the outlaw "pharma bro" Martin Shkreli, who worked with the inept (Corrupt? IMO) FDA to create a tax on the company's treasury by urging yet another CRL that delayed entry into the market, costing valuable time and money. Most of all, have the executive team tatooed with the words "No excuses, only results" and a sign at the board room entrance that says "check your egos at the door". With many of the other long investors on this board, I'm tired of quarterly presentations filled with meaningless statistics and inept observations. Please don't waste our time, just get the flipping job done or move over and let someone else who has energy and tenacity to do the job have a go. Chris C Long and running out of patience. |
|
|
|
Post by matt on Nov 7, 2019 10:50:48 GMT -5
If this was a preliminary is there a date that a final must be filed by ? Yes, the 10-Q is due 40 days after the end of the quarter for accelerated filers (which MNKD is) plus a grace period if the filing date is on a weekend or holiday. Do the math and that works out to November 14. The auditors have likely reviewed and passed on the numbers published in the press release; that is pretty standard for any public company. The details in the footnote disclosures sometimes take an extra week or two. Quarterly filing only get a review which is a lot less involved than the annual audit. |
|
|
|
Post by sportsrancho on Nov 7, 2019 10:54:40 GMT -5
Whiskeyqueen..
$MNKD For ANY relationship to survive and go the distance there must be mutual trust, there must be honesty, admitting when you were wrong. Promptly. What Michael Castagna seems to lack is a sense of humility. If he were to have even once in the last 900~ days at being our ceo admitted where he went wrong, and there have been many, many instances of this, I would have tons more respect for him and his character. It is very hard to respect a person who seems to do no wrongs...Sorry, but if I had not once in my marriage admitted to my wrongs and not shown a sense of humility, I would be a single, miserable person. Unless I was a sociopath....M.C. What are you dude?
|
|
|
|
Post by rickf on Nov 7, 2019 10:56:04 GMT -5
I totally echo Chris-C 's comments!! I too am 6 figures underwater and am unable to retire as a result! (no one has to tell me - it is my fault for risking like I did!) I believed in Al Mann's dream!
|
|
|
|
Post by standup on Nov 7, 2019 11:15:01 GMT -5
Afrezza Q3 U.S. net revenue failed to follow the annual trend of increasing throughout the year for the first time.
Anticipating future short falls he comments, "We've met our revenue covenants as of September 30 and maintain an open dialog with our new lending partner about our sales trends and actions we're taking improve them, some of which I'll discuss in a high level detail in a few slides. I believe we have a strong relationship with MidCap, and we will successfully work together to resolve any issues that may rise throughout the term of our loan."
Michael Castagna has demonstrated he is incapable of guiding the company forward in a meaningful way.
No offense to those who continue to support him but you are deluding yourselves.
|
|
|
|
Post by ktim on Nov 7, 2019 11:48:41 GMT -5
Afrezza Q3 U.S. net revenue failed to follow the annual trend of increasing throughout the year for the first time. Anticipating future short falls he comments, "We've met our revenue covenants as of September 30 and maintain an open dialog with our new lending partner about our sales trends and actions we're taking improve them, some of which I'll discuss in a high level detail in a few slides. I believe we have a strong relationship with MidCap, and we will successfully work together to resolve any issues that may rise throughout the term of our loan." Michael Castagna has demonstrated he is incapable of guiding the company forward in a meaningful way. No offense to those who continue to support him but you are deluding yourselves. I haven't yet had time to listen to the call, but it seems that should have been addressed. The Symphony numbers increased so there is some sort of distribution channel issue coming into play. Ordinarily that would be covered within the call. Of course, little is done in the ordinary way when it comes to MNKD. |
|
|
|
Post by awesomo on Nov 7, 2019 11:53:57 GMT -5
Afrezza Q3 U.S. net revenue failed to follow the annual trend of increasing throughout the year for the first time. Anticipating future short falls he comments, "We've met our revenue covenants as of September 30 and maintain an open dialog with our new lending partner about our sales trends and actions we're taking improve them, some of which I'll discuss in a high level detail in a few slides. I believe we have a strong relationship with MidCap, and we will successfully work together to resolve any issues that may rise throughout the term of our loan." Michael Castagna has demonstrated he is incapable of guiding the company forward in a meaningful way. No offense to those who continue to support him but you are deluding yourselves. I haven't yet had time to listen to the call, but it seems that should have been addressed. The Symphony numbers increased so there is some sort of distribution channel issue coming into play. Ordinarily that would be covered within the call. Of course, little is done in the ordinary way when it comes to MNKD. Of course it’s not addressed. Mike is great at spin, everything is great and everyone is happy. Maybe this is related to why they released unaudited “preliminary financial statements” and why their Chief Compliance Officer is no more. |
|
|
|
Post by harryx1 on Nov 7, 2019 11:59:53 GMT -5
Harryx1 21m $MNKD Get rid of those people and hire an NIH grant expert to get the remaining pipeline into phase 1 trials at a low cost. That would be money worth spending. grants.nih.gov/grants/oer.htmlaborer75 $MNKD Anyone know why we pay Stuart Tross? He hasn't done shit to add good talent to our sales team. WTF do we need to waste money on a Chief Peoples Officer for? Also, has Pat McCaully done enough to warrant his salary and employment? This guy hasn't even gotten a base hit let alone score a run. |
|
|
|
Post by mytakeonit on Nov 7, 2019 12:01:02 GMT -5
For anyone that feels totally underwater ... buy a snorkel ... or average down. I checked out my E*Trade account this morning and was surprised to see ... that MNKD's earnings beat analysts estimates by 2.8 cents. I thought the 6 cents loss estimate was what we were faced with, but I was Wong again. So maybe not a big win, but it brightened up my morning.  Until I saw that volume was low again and we are down another 4 cents. BUT, my cash influx will in maybe next weekend so another buying opportunity is headed my way. Wow! What a seesaw week. Glad that I still have more wine. But, that's mytakeonit |
|
|
|
Post by uvula on Nov 7, 2019 13:29:14 GMT -5
Every time I bought more to avg down the price subsequently dropped even further. Technically my avg price is lower but my losses are larger. No more.
|
|
|
|
Post by awesomo on Nov 7, 2019 13:47:25 GMT -5
Harryx1 21m $MNKD Get rid of those people and hire an NIH grant expert to get the remaining pipeline into phase 1 trials at a low cost. That would be money worth spending. grants.nih.gov/grants/oer.htmlaborer75 $MNKD Anyone know why we pay Stuart Tross? He hasn't done shit to add good talent to our sales team. WTF do we need to waste money on a Chief Peoples Officer for? Also, has Pat McCaully done enough to warrant his salary and employment? This guy hasn't even gotten a base hit let alone score a run. Hey now, I'm sure Stuart Tross throws excellent Halloween parties. We've all seen the photos. |
|
Until I saw that volume was low again and we are down another 4 cents. 